RU2002124602A - Композиция для мужской контрацепции, включающая норэтистерон - Google Patents
Композиция для мужской контрацепции, включающая норэтистеронInfo
- Publication number
- RU2002124602A RU2002124602A RU2002124602/15A RU2002124602A RU2002124602A RU 2002124602 A RU2002124602 A RU 2002124602A RU 2002124602/15 A RU2002124602/15 A RU 2002124602/15A RU 2002124602 A RU2002124602 A RU 2002124602A RU 2002124602 A RU2002124602 A RU 2002124602A
- Authority
- RU
- Russia
- Prior art keywords
- net
- derivative
- testosterone
- paragraphs
- administered
- Prior art date
Links
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 title claims abstract 45
- 229940053934 norethindrone Drugs 0.000 title claims abstract 21
- 239000000203 mixture Substances 0.000 title claims abstract 20
- 229960000746 testosterone undecanoate Drugs 0.000 claims abstract 18
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims abstract 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract 16
- 239000000583 progesterone congener Substances 0.000 claims abstract 16
- 239000003098 androgen Substances 0.000 claims abstract 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract 14
- -1 testosterone ester Chemical class 0.000 claims abstract 11
- 229960003604 testosterone Drugs 0.000 claims abstract 9
- 230000001548 androgenic effect Effects 0.000 claims abstract 6
- 230000001076 estrogenic effect Effects 0.000 claims abstract 6
- 229940079593 drug Drugs 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 28
- 238000000034 method Methods 0.000 claims 24
- 238000010255 intramuscular injection Methods 0.000 claims 16
- 239000007927 intramuscular injection Substances 0.000 claims 16
- 238000010253 intravenous injection Methods 0.000 claims 9
- 239000007929 subcutaneous injection Substances 0.000 claims 9
- 238000010254 subcutaneous injection Methods 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000002513 implantation Methods 0.000 claims 7
- 238000007920 subcutaneous administration Methods 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 5
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims 4
- 239000006201 parenteral dosage form Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000003923 ethanoic acid ester group Chemical group 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- 229960000921 testosterone cypionate Drugs 0.000 claims 1
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 claims 1
- 229960003484 testosterone enanthate Drugs 0.000 claims 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims 1
- 229960001712 testosterone propionate Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract 3
- 206010003883 azoospermia Diseases 0.000 abstract 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 abstract 1
- 239000002583 male contraceptive agent Substances 0.000 abstract 1
- 229960001652 norethindrone acetate Drugs 0.000 abstract 1
- 229960002082 norethindrone enanthate Drugs 0.000 abstract 1
- 208000008634 oligospermia Diseases 0.000 abstract 1
- 230000021595 spermatogenesis Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 150000003515 testosterones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50372900A | 2000-02-15 | 2000-02-15 | |
| EP00200493 | 2000-02-15 | ||
| EP00200493.5 | 2000-02-15 | ||
| US09/503,729 | 2000-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002124602A true RU2002124602A (ru) | 2004-03-10 |
Family
ID=26071832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002124602/15A RU2002124602A (ru) | 2000-02-15 | 2001-02-15 | Композиция для мужской контрацепции, включающая норэтистерон |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP1666044B1 (enExample) |
| JP (1) | JP2003522795A (enExample) |
| KR (1) | KR20020086905A (enExample) |
| CN (1) | CN1423560A (enExample) |
| AT (2) | ATE474580T1 (enExample) |
| AU (1) | AU2001230447A1 (enExample) |
| BG (1) | BG107066A (enExample) |
| BR (1) | BR0108411A (enExample) |
| CA (1) | CA2398063A1 (enExample) |
| CY (1) | CY1106639T1 (enExample) |
| CZ (1) | CZ20022691A3 (enExample) |
| DE (2) | DE60142647D1 (enExample) |
| DK (1) | DK1267885T3 (enExample) |
| EE (1) | EE200200454A (enExample) |
| ES (1) | ES2282230T3 (enExample) |
| HK (1) | HK1049442B (enExample) |
| HU (1) | HUP0300128A3 (enExample) |
| IL (1) | IL151219A0 (enExample) |
| MX (1) | MXPA02007675A (enExample) |
| NO (1) | NO20023607L (enExample) |
| PL (1) | PL357185A1 (enExample) |
| PT (1) | PT1267885E (enExample) |
| RU (1) | RU2002124602A (enExample) |
| SI (1) | SI1267885T1 (enExample) |
| SK (1) | SK11602002A3 (enExample) |
| WO (1) | WO2001060376A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10234525A1 (de) * | 2002-07-25 | 2004-02-05 | Schering Ag | Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| WO2004011663A2 (de) | 2002-07-24 | 2004-02-05 | Schering Aktiengesellschaft | Mikrobiologische verfahren zur herstellung von 7alpha-substituierten 11alpha-hydroxysteroiden |
| AU2003251636B2 (en) * | 2002-07-25 | 2009-10-22 | Bayer Schering Pharma Aktiengesellschaft | Composition containing an androgenous 11beta-halogen steroid and a progestational hormone, and male contraceptive based on said composition |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| CN101352443B (zh) * | 2007-07-23 | 2011-01-12 | 中国科学院动物研究所 | 哺乳动物雄性不育剂 |
| KR102496504B1 (ko) | 2018-03-23 | 2023-02-06 | 라보라뚜아르 마조르 | 남성 피임을 위한 비호르몬 조성물 및 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714420A1 (de) * | 1976-06-01 | 1977-12-08 | Int Pregnancy Advisory Service | Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| DE19650352A1 (de) * | 1996-12-04 | 1998-07-30 | Jenapharm Gmbh | Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann |
-
2001
- 2001-02-15 CA CA002398063A patent/CA2398063A1/en not_active Abandoned
- 2001-02-15 JP JP2001559472A patent/JP2003522795A/ja active Pending
- 2001-02-15 SK SK1160-2002A patent/SK11602002A3/sk unknown
- 2001-02-15 PT PT01902590T patent/PT1267885E/pt unknown
- 2001-02-15 DK DK01902590T patent/DK1267885T3/da active
- 2001-02-15 EE EEP200200454A patent/EE200200454A/xx unknown
- 2001-02-15 ES ES01902590T patent/ES2282230T3/es not_active Expired - Lifetime
- 2001-02-15 BR BR0108411-9A patent/BR0108411A/pt not_active IP Right Cessation
- 2001-02-15 AT AT06075322T patent/ATE474580T1/de not_active IP Right Cessation
- 2001-02-15 AU AU2001230447A patent/AU2001230447A1/en not_active Abandoned
- 2001-02-15 CN CN01808041A patent/CN1423560A/zh active Pending
- 2001-02-15 WO PCT/IB2001/000188 patent/WO2001060376A1/en not_active Ceased
- 2001-02-15 DE DE60142647T patent/DE60142647D1/de not_active Expired - Lifetime
- 2001-02-15 HK HK03101578.5A patent/HK1049442B/en not_active IP Right Cessation
- 2001-02-15 CZ CZ20022691A patent/CZ20022691A3/cs unknown
- 2001-02-15 IL IL15121901A patent/IL151219A0/xx unknown
- 2001-02-15 DE DE60127103T patent/DE60127103T2/de not_active Expired - Lifetime
- 2001-02-15 EP EP06075322A patent/EP1666044B1/en not_active Expired - Lifetime
- 2001-02-15 HU HU0300128A patent/HUP0300128A3/hu unknown
- 2001-02-15 RU RU2002124602/15A patent/RU2002124602A/ru not_active Application Discontinuation
- 2001-02-15 EP EP01902590A patent/EP1267885B8/en not_active Expired - Lifetime
- 2001-02-15 SI SI200130726T patent/SI1267885T1/sl unknown
- 2001-02-15 AT AT01902590T patent/ATE355844T1/de active
- 2001-02-15 MX MXPA02007675A patent/MXPA02007675A/es unknown
- 2001-02-15 PL PL01357185A patent/PL357185A1/xx not_active Application Discontinuation
- 2001-02-15 KR KR1020027010715A patent/KR20020086905A/ko not_active Withdrawn
-
2002
- 2002-07-30 NO NO20023607A patent/NO20023607L/no not_active Application Discontinuation
- 2002-09-05 BG BG107066A patent/BG107066A/xx unknown
-
2007
- 2007-06-05 CY CY20071100743T patent/CY1106639T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2253423T3 (es) | Formulacion de un ester de testosterona para uso humano. | |
| CA2908571C (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| KR100802366B1 (ko) | 풀베스트란트 제제 | |
| HU176742B (en) | Process for preparing pharmaceutical preparations containing new estradiol-17beta-estres with estrogen activity for oral application | |
| AU2001291775A1 (en) | Testosterone ester formulation for human use | |
| EP1524983B1 (de) | Zusammensetzung, enthaltend ein androgenes 11-b-halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung | |
| AU2002338277B2 (en) | Estrogen replacement therapy | |
| RU2002124602A (ru) | Композиция для мужской контрацепции, включающая норэтистерон | |
| KR19990077156A (ko) | 폐경기 증상의 치료 또는 예방을 위한 약학적 조성물의제조를 위한 3,4-디페닐크로만의 사용 | |
| EP0479867B1 (en) | Compositions useful as contraceptives in males | |
| US4076811A (en) | Novel agents and methods for treatment of climacteric disturbances | |
| JP2003522795A5 (enExample) | ||
| CA2483770A1 (en) | Trimegestone and estrogens for treating post menopausal disorders | |
| BR0014952A (pt) | Medicamento contraceptivo e seu modo de preparação | |
| JP2005532336A5 (enExample) | ||
| CN1655848A (zh) | 新依托孕烯酯的用途 | |
| HU179942B (en) | Process for preparing injectable pharmaceutical compositions against internal parasites,particularly for the treatment and prevention of rot of sheep | |
| CA2412864A1 (en) | Methods of making, using and pharmaceutical formulations comprising 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestra-4,14-dien-3-one and 17 esters thereof | |
| ZA200501653B (en) | Composition containing an androgenous 11ß-halogen steroid and a progestational hormone, and male contraceptive based on said composition | |
| NZ537903A (en) | Composition containing an androgenic 11beta-halogen steroid and a gestagen as well as a male contraceptive agent based on this composition | |
| PT96127A (pt) | Metodos para o alivio dos sintomas da menopausa processo para a preparacao das respectivas composicoes a base de melatonina em combinacao com estrogenios | |
| KR960010006A (ko) | 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20070716 |